Dynavax initiated with a Neutral at Goldman Sachs

Goldman Sachs analyst Paul Choi initiated coverage of Dynavax with a Neutral rating and $20 price target. The analyst thinks there is limited potential upside for the shares from current levels given the company’s mostly early stage pipeline and scarcity of near-term catalysts. The firm sees more compelling risk/rewards elsewhere in its coverage.